William Blair analyst Andy Hsieh noted on Monday that Viking’s results surpassed Wall Street expectations and outperformed ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Although it is administered via injection, rather than in pill form, early results show a 200% higher weight loss reduction ...

The controlling shareholder in Novo Nordisk put in a request for EU approval for the deal on Oct. 31. The EU antitrust ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Many health plans do not cover semaglutide for weight loss, making compounded versions a more affordable alternative. In November 2023, Novo Nordisk sued Florida compounding pharmacies over ...

Novo Nordisk’sNOVO.B-1.06%decrease ... in the company’s blockbuster Ozempic and Wegovy diabetes and weight-loss drugs, and was tested in the trial on diabetic patients who also suffered ...

That bar was set by an experimental pill from Novo Nordisk that demonstrated 5% weight loss in four weeks, he noted. Hsieh also said Viking's pill showed a "highly benign tolerability profile ...